Trial Profile

Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Nivolumab (Primary) ; Hyaluronidase
Indications Carcinoma; Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
Focus Pharmacokinetics
Acronyms CheckMate 8KX
Sponsors Bristol-Myers Squibb

Most Recent Events

06 Dec 2024 Status changed from active, no longer recruiting to completed.
22 Jul 2024 Planned End Date changed from 7 Mar 2025 to 12 Sep 2024.
18 Nov 2022 Planned End Date changed from 14 Jul 2025 to 7 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com